Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Lancet Haematol. 2023 Jan;10(1):e46-e58. doi: 10.1016/S2352-3026(22)00292-7. Epub 2022 Nov 10.
Lancet Haematol. 2023.
PMID: 36370742
Clinical Trial.
Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia.
Ghobrial IM, Redd R, Armand P, Banwait R, Boswell E, Chuma S, Huynh D, Sacco A, Roccaro AM, Perilla-Glen A, Noonan K, MacNabb M, Leblebjian H, Warren D, Henrick P, Castillo JJ, Richardson PG, Matous J, Weller E, Treon SP.
Ghobrial IM, et al. Among authors: henrick p.
Leukemia. 2015 Dec;29(12):2338-46. doi: 10.1038/leu.2015.164. Epub 2015 Jul 3.
Leukemia. 2015.
PMID: 26139427
Clinical Trial.
Item in Clipboard
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma.
Laubach JP, Liu CJ, Raje NS, Yee AJ, Armand P, Schlossman RL, Rosenblatt J, Hedlund J, Martin M, Reynolds C, Shain KH, Zackon I, Stampleman L, Henrick P, Rivotto B, Hornburg KTV, Dumke HJ, Chuma S, Savell A, Handisides DR, Kroll S, Anderson KC, Richardson PG, Ghobrial IM.
Laubach JP, et al. Among authors: henrick p.
Clin Cancer Res. 2019 Jan 15;25(2):478-486. doi: 10.1158/1078-0432.CCR-18-1325. Epub 2018 Oct 2.
Clin Cancer Res. 2019.
PMID: 30279233
Free PMC article.
Clinical Trial.
Item in Clipboard
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.
Ghobrial IM, Liu CJ, Zavidij O, Azab AK, Baz R, Laubach JP, Mishima Y, Armand P, Munshi NC, Basile F, Constantine M, Vredenburgh J, Boruchov A, Crilley P, Henrick PM, Hornburg KTV, Leblebjian H, Chuma S, Reyes K, Noonan K, Warren D, Schlossman R, Paba-Prada C, Anderson KC, Weller E, Trippa L, Shain K, Richardson PG.
Ghobrial IM, et al. Among authors: henrick pm.
Am J Hematol. 2019 Nov;94(11):1244-1253. doi: 10.1002/ajh.25627. Epub 2019 Oct 4.
Am J Hematol. 2019.
PMID: 31456261
Free article.
Clinical Trial.
Item in Clipboard
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma.
Ghobrial IM, Liu CJ, Redd RA, Perez RP, Baz R, Zavidij O, Sklavenitis-Pistofidis R, Richardson PG, Anderson KC, Laubach J, Henrick P, Savell A, Reyes K, Hornburg K, Chuma S, Sabbatini P, Robbins MD, Becker PS.
Ghobrial IM, et al. Among authors: henrick p.
Clin Cancer Res. 2020 Jan 15;26(2):344-353. doi: 10.1158/1078-0432.CCR-19-0647. Epub 2019 Oct 31.
Clin Cancer Res. 2020.
PMID: 31672767
Clinical Trial.
Item in Clipboard
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients.
Sklavenitis-Pistofidis R, Capelletti M, Liu CJ, Reidy M, Zavidij O, Huynh D, Henrick P, Savell A, Reyes K, Rivotto B, Bustoros M, Perilla-Glen A, Trippa L, Castillo JJ, Treon SP, Ghobrial IM.
Sklavenitis-Pistofidis R, et al. Among authors: henrick p.
Blood. 2018 Dec 13;132(24):2608-2612. doi: 10.1182/blood-2018-07-863241. Epub 2018 Oct 26.
Blood. 2018.
PMID: 30366921
Free PMC article.
Clinical Trial.
No abstract available.
Item in Clipboard
Cite
Cite